Excellence Future

Beijing Excellence Future International Pharmaceutical Technology Development Co., Ltd. (Beijing Excellence Future International Consulting Co., Ltd.) was established in 2002. It is a Contract Research Organization (CRO) specializing in providing professional services throughout the entire clinical trial process for pharmaceutical companies. Since its inception, it has undertaken over 1,600 clinical research projects for new drugs, medical devices, and post-marketing drugs (including SMO projects), covering a wide range of specialties including oncology, psychiatry and neurology, respiratory, cardiovascular and cerebrovascular diseases, orthopedics, pediatrics, gastroenterology, anesthesiology, and other fields, encompassing almost all medical sub-disciplines. Through over 20 years of solid accumulation, Excellence Future has built a professional and stable team. As of 2024, the company has over 1,600 employees and cooperates with nearly a thousand research centers across 31 provinces, municipalities, and autonomous regions nationwide. Its service areas are divided into seven major regions: North China, Northeast China, East China, Central China, South China, Southwest China, and Northwest China, covering nearly 300 cities. The company has established eight professional clinical research sub-platforms including oncology, psychiatry and neurology, cardiovascular and cerebrovascular diseases, respiratory, pediatrics, gastroenterology, and orthopedics. It also sets up professional departments such as Quality Control Center, Academic Center, Project Promotion Center, Medical Device Center, and Registration Center, as well as 17 subsidiaries including Excellence Tongzhou (drug development), Excellence Angel (SMO), and Tianjin Aide (third-party audit). Excellence Future holds national high-tech enterprise certification, ISO9001 quality system certification, and 34 high-quality qualifications including authorized invention patents, software copyrights, and trademarks. For eight consecutive years, it has been recognized as a China Pharmaceutical Law-abiding and Integrity Enterprise, AAA-level Credit Enterprise, and has received honors such as Beijing Municipal Science and Technology Commission's "Excellent CRO Enterprise" title and the Best Clinical CRO Golden Horse Award. Over the years, Excellence Future has been committed to providing enterprises with "one-stop, full life-cycle coverage" professional services and has established good cooperative relationships with over 1,000 domestic and international R&D and pharmaceutical companies and research institutes. After more than 20 years of development, the company's business has expanded from clinical CRO to SMO and preclinical CRO services, and it has developed unique features in key stages of drug development including prescription screening, process validation, new drug application and project initiation, early intervention for innovative drugs, preclinical research, clinical trials, regulatory submission, risk management planning, post-marketing academic promotion, top-level design, project application, and cultivation of major varieties. With its standardized business process norms, rich operational experience, comprehensive quality control system, extensive expert resources, and stable project management and execution team, the company has become one of the industry-recognized high-quality clinical research CRO companies with both integrity and professionalism.